Healiva acquires cell therapy manufacturing assets from B. Braun

Healiva announced the acquisition of critical manufacturing assets, including a qualified cell bank, from B. Braun Medical AG Switzerland to accelerate the launch of its EpiDex cell therapy.

“This transaction will enable Healiva to accelerate the launch of EpiDex, which is projected for Q4 2023.”biospace.com

• 1 source
• biospace.comHealiva® Acquires Critical Cell Therapy Manufacturing Assets From B. Braun - BioSpaceAnnalee ArmstrongNov 21, 2022

Summarized from public sources; check the original articles before acting on it.